Article

In Patients with JAK2 Unmutated CMN, Are CalR and MPL Gene Mutations Predictive of Diagnosis or Clinical Course?

2025-01-29

Abstract excerpt

Philadelphia (Ph) negative myeloproliferative neoplasms (MPNs) are disorders caused by abnormal proliferation of myeloid cells in the peripheral blood. Mutations that are responsible for the majority of these cases are those affecting Janus kinase 2 (JAK2), Calreticulin (CalR), and myeloproliferative leukemia virus oncogene (MPL). In this study, we aimed to assess the frequency of CalR and MPL gene mutations and t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 56ad771f-ef45-59fa-83cc-187c21217a58
DOI: 10.20944/preprints202501.2157.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In Patients with JAK2 Unmutated CMN, Are CalR and MPL Gene Mutations Predictive of Diagnosis or Clinical Course?DOI 10.20944/preprints202501.2157.v1Read

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL.Semantic proximity Read

JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.Semantic proximity Read

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasmsSemantic proximity Read

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.Semantic proximity Read

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Semantic proximity Read

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.Semantic proximity Read

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.Semantic proximity Read

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.Semantic proximity Read

Targets in MPNs and potential therapeutics.Semantic proximity Read

CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.Semantic proximity Read

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.Semantic proximity Read

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Semantic proximity Read